Brian Gallagher is joining London-based Abingworth as a partner based in the life sciences investment firm’s Boston office. Gallagher comes to Abingworth from SR One, the venture capital arm of GlaxoSmithKline (NYSE: [[ticker:GSK]]), where was a partner. Before SR One, Gallagher was senior director of corporate development at Sirtris Pharmaceuticals, which was acquired by GSK in 2008.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
